Literature DB >> 11387073

Distension Arthrography in Frozen Shoulder Syndrome.

Marc Wybier1, Caroline Parlier-Cuau, Marie-Christine Baque, Pierre Champsaur, Albert Haddad, Jean-Denis Laredo.   

Abstract

Distension arthrography under fluoroscopic control may be useful in frozen shoulder syndrome. The technique consists of an intra-articular injection of 2 to 3 mL of contrast material, 3 mL of 2% lidocaine, 1.5 mL of cortivazol, and distension of the joint capsule with 30 to 40 mL of refrigerated sterile saline solution. This injection is immediately followed by a physiotherapy program. The authors report their experience of distension arthography in 30 shoulders. Results were good to very good in 90% of cases at 40-day follow-up. No recurrence of a frozen shoulder syndrome was observed and no complications were encountered in this series.

Entities:  

Year:  1997        PMID: 11387073     DOI: 10.1055/s-2008-1080145

Source DB:  PubMed          Journal:  Semin Musculoskelet Radiol        ISSN: 1089-7860            Impact factor:   1.777


  4 in total

1.  Effect of Intra-articular Hyaluronic Acid Injection on Hemiplegic Shoulder Pain After Stroke.

Authors:  Myung Hun Jang; Chang-Hyung Lee; Yong-Il Shin; Soo-Yeon Kim; Sung Chul Huh
Journal:  Ann Rehabil Med       Date:  2016-10-31

2.  Targeted ultrasound-guided hydrodilatation via the rotator interval for adhesive capsulitis.

Authors:  Philip Yoong; Stephen Duffy; David McKean; Nabil P Hujairi; Ramy Mansour; James L Teh
Journal:  Skeletal Radiol       Date:  2014-11-21       Impact factor: 2.199

3.  Lessons learnt from the painful shoulder; a case series of malignant shoulder girdle tumours misdiagnosed as frozen shoulder.

Authors:  Gerald My Quan; Derek Carr; Steven Schlicht; Gerard Powell; Peter Fm Choong
Journal:  Int Semin Surg Oncol       Date:  2005-01-12

4.  Hydrodilatation, corticosteroids and adhesive capsulitis: a randomized controlled trial.

Authors:  Einar Kristian Tveitå; Rana Tariq; Sølve Sesseng; Niels Gunnar Juel; Erik Bautz-Holter
Journal:  BMC Musculoskelet Disord       Date:  2008-04-19       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.